NSMB | 新型芋螺毒素多肽实现外周镇痛，为非阿片类镇痛药研发提供新思路
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - A Nature Structural & Molecular Biology paper (Harald Sitte, Medical University of Vienna, with Xu Huaqiang's team at SIMM/CAS) reports χ-conotoxin AoIA, a cone-snail (Conus araneosus) peptide that selectively inhibits the noradrenaline transporter (NET) and produces analgesia via subcutaneous injection — a possible route to non-opioid painkillers. Note: this item is biomedical structural biology, with no AI/ML component described.
- Cryo-EM structure of the AoIA–human NET complex resolves the binding mode and inhibition mechanism, providing a template for structure-based optimization.
- AoIA is highly selective for NET over the closely related SERT and DAT, offering structural insight into neurotransmitter-transporter substrate recognition and selectivity.
- Pharmacology indicates no action on opioid receptors or other known pain targets; analgesia is attributed to NET inhibition boosting endogenous noradrenergic pain suppression.
- In mice, it relieved inflammatory pain after subcutaneous dosing (unlike intrathecal-only Ziconotide) but showed no clear effect in acute pain models and no observed sedation or motor-coordination deficits; preclinical/clinical work is still needed.
Sources (1)
NSMB | 新型芋螺毒素多肽实现外周镇痛，为非阿片类镇痛药研发提供新思路
TL;DR - A Nature Structural & Molecular Biology paper (Harald Sitte, Medical University of Vienna, with Xu Huaqiang's team at SIMM/CAS) reports χ-conotoxin AoIA, a cone-snail (Conus araneosus) peptide that selectively inhibits the noradrenaline transporter (NET) and produces analgesia via subcutaneous injection — a possible route to non-opioid painkillers. Note: this item is biomedical structural biology, with no AI/ML component described.
- Cryo-EM structure of the AoIA–human NET complex resolves the binding mode and inhibition mechanism, providing a template for structure-based optimization.
- AoIA is highly selective for NET over the closely related SERT and DAT, offering structural insight into neurotransmitter-transporter substrate recognition and selectivity.
- Pharmacology indicates no action on opioid receptors or other known pain targets; analgesia is attributed to NET inhibition boosting endogenous noradrenergic pain suppression.
- In mice, it relieved inflammatory pain after subcutaneous dosing (unlike intrathecal-only Ziconotide) but showed no clear effect in acute pain models and no observed sedation or motor-coordination deficits; preclinical/clinical work is still needed.